Close
Enter your
text here

clinical trial

Parc Taulí will evaluate a new therapy for Angelman syndrome
 Parc Taulí will evaluate a new therapy for Angelman syndrome 1080 608 Oriol Capell
By:
The center is participating in an international clinical trial that seeks to improve patients' quality of life by addressing sleep, communication and motor disorders. read more
Parc Taulí begins a clinical study to test a new oncology drug in humans for the first time
 Parc Taulí begins a clinical study to test a new oncology drug in humans for the first time 1080 608 Oriol Capell
By:
The study will evaluate the safety and efficacy of a molecule that blocks a key enzyme for DNA repair in cancer cells read more
An international study proves that the combination of simvastatin and rifaximin is not effective in patients with decompensated cirrhosis
 An international study proves that the combination of simvastatin and rifaximin is not effective in patients with decompensated cirrhosis 1080 608 Mireia Córcoles
By:
A group of researchers from I3PT has collaborated on an important European study whose results have been published in the prestigious journal JAMA read more
Parc Taulí is leading a clinical trial to evaluate the clinical and economic benefits of 3D digital surgery
 Parc Taulí is leading a clinical trial to evaluate the clinical and economic benefits of 3D digital surgery 1080 608 Oriol Capell
By:
The results obtained will make it possible to determine if digital surgery is a profitable methodology and, therefore, can become a common and standardized practice in the rest of the country's hospital centers read more
Clinical trial begins for AI software to detect lung cancer in unanalyzed X-rays
Clinical trial begins for AI software to detect lung cancer in unanalyzed X-rays 1080 608 Oriol Capell
By:
This tool, named Optimal XR, aims to prevent potentially malignant lung nodules from continuing to go unnoticed by diagnosing them in a timely manner read more
I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome
 I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome 1080 608 Mireia Córcoles
By:
The Phase IIa study will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with FXS, the most common form of inherited intellectual disability without a specific treatment read more
  • 1
  • 2
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.